An interventional study of self care educational program for the study group and Routine care in Rheumatoid Arthritis (RA), sponsored by Assiut University. Not yet recruiting. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Assiut University · Not applicable, Interventional, and Treatment
Among 49 studies in Arthritis, Rheumatoid by Assiut University — 23 open to participants now, 23 under way, none of them phase 3. Arthritis, Rheumatoid · Assiut University.
Among the 49 studies in Arthritis, Rheumatoid by Assiut University, this one is one of 10 that started in 2026, is one of 5 with no phase, reaches primary completion later than 12 of the 22 other live ones, and was the 42nd registered.
3,332 studies on the registry are indexed under Arthritis, Rheumatoid; 443 are open to participants now.
This study's planned enrollment of 110 is above the median of 96 across 2,220 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →23 of the 49 studies in Arthritis, Rheumatoid by Assiut University are open now, in 1 country. Each count lists the studies.
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →49 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
Median enrollment 90 across the 6 interventional studies, 80 across the 43 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
10 of the studies in Arthritis, Rheumatoid by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06691997Assiut UniversityThe Impact of Glycemic Control on Rheumatoid Arthritis Disease Activity on Diabetic Patients | 2026-11-14 |
| NCT07761767Assiut UniversitySelf-Care Education for Joint Stiffness and Functional Ability in Rheumatoid Arthritis | 2027-01-01 |
| NCT07129837Assiut UniversitySerum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients. | 2027-03 |
| NCT07657156Assiut UniversityMusculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis | 2027-07 |
| NCT07105566Assiut UniversityTriosephosphate Isomerase Level in Relation to Rheumatoid Aerthritis Activity and Structural Damage | 2027-09 |
Among the 49 studies in Arthritis, Rheumatoid by Assiut University, from their registry updates:
Nothing recorded among them since 2026-09-25.
Rheumatoid arthritis is a chronic inflammatory autoimmune disease that may cause joint stiffness, pain, reduced mobility, and impaired functional ability. Self-care education may help patients improve their knowledge and practices related to disease management, joint protection, physical activity, exercise, energy conservation, and symptom management.
This study aims to evaluate the effectiveness of a self-care educational program on joint stiffness and functional ability among patients with rheumatoid arthritis. Participants will be assigned to either a study group or a control group. The study group will receive the self-care educational program in addition to routine care, while the control group will receive routine care only. Joint stiffness and functional ability will be assessed before and after implementation of the educational program.
Rheumatoid arthritis is associated with joint inflammation, stiffness, pain, reduced physical functioning, and limitations in activities of daily living. Appropriate self-care practices may contribute to improving patients' ability to manage symptoms and maintain functional independence.
The self-care educational program will provide patients with information and practical guidance regarding rheumatoid arthritis and its management. The program may include disease-related knowledge, medication adherence, joint protection techniques, exercise, energy conservation, activity modification, symptom management, and appropriate self-care practices.
Participants will be divided into two groups:
Study Group: Participants will receive the self-care educational program in addition to routine care.
Control Group: Participants will receive routine care only. Joint stiffness and functional ability will be assessed at baseline and after implementation of the educational program. The outcomes of the study group will be compared with those of the control group to determine the effectiveness of the program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who agree to participate in the study.
Exclusion Criteria:
Patients who have participated in a similar self-care educational program recently.
Participants in the intervention group will receive a self-care educational program designed to improve self-care practices, reduce joint stiffness, and improve functional ability in patients with rheumatoid arthritis. The program will include education about rheumatoid arthritis, joint protection techniques, appropriate exercises, medication use, and self-care practices.
Behavioral: self care educational program for the study group
Participants will receive usual care without the self-care educational program.
Other: Routine care
study group Participants will receive the self-care educational program in addition to usual care.
The control group will receive the routine care provided to patients with rheumatoid arthritis and will not receive the self-care educational program during the study period.
change in joint stiffness
Duration of morning joint stiffness will be assessed using a single-item patient-reported outcome measure. Participants will report the duration of their morning joint stiffness in minutes. Durations greater than 12 hours (720 minutes) will be recorded as 720 minutes. Higher values indicate a longer duration of morning joint stiffness. Severity of morning joint stiffness will be assessed using a single-item patient-reported outcome measure. Participants will rate the overall severity of their morning joint stiffness on a numerical rating scale ranging from 0 to 10, where 0 indicates no joint stiffness and 10 indicates the worst possible joint stiffness. Higher scores indicate greater severity of joint stiffness.
Time frame: Baseline and 3 months after completion of the intervention.
functional ability
Functional ability will be assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI). The HAQ-DI assesses functional ability across eight areas: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 (without any difficulty) to 3 (unable to do). The overall score ranges from 0 to 3, with 0 indicating no disability and 3 indicating severe disability. Higher scores indicate worse functional ability and greater disability.
Time frame: Baseline and 3 months after completion of the intervention.
No study locations are listed for this record.
Plan to share: No — There are no plans to make individual participant data available to other researchers.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
Of 292 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 4 months is below that.
Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.